18:43 , Oct 18, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Brain cancer Patient sample and mouse studies suggest inhibiting Notch 1 could help treat metastatic medulloblastoma. In primary tumor samples from medulloblastoma patients, levels of Notch 1 were higher in patients with metastases than...
17:40 , Sep 26, 2018 |  BC Innovations  |  Distillery Therapeutics

Gastrointestinal; cancer

INDICATION: Adenomatous polyps; colorectal cancer Patient sample, cell culture and mouse studies suggest inhibiting JAG1 could help treat familial adenomatous polyposis (FAP) and Notch 1-positive, MFNG-negative colorectal cancers. In Notch 1-positive tumor samples from 198...
23:05 , Jan 18, 2018 |  BC Innovations  |  Translation in Brief

A notch for tankyrase

New York University School of Medicine researchers have identified a multitude of tankyrase targets, including factors in the Notch and Wnt/β-catenin pathways, that offer new opportunities for tankyrase inhibitors in cancer. In a...
21:45 , Jul 13, 2017 |  BC Innovations  |  Targets & Mechanisms

Insider signaling

With evidence mounting that cell surface receptors keep signaling after they are internalized, a Takeda-backed study from Monash University has shown how the phenomenon could solve the riddle of why antagonists of the substance P...
20:18 , Jul 7, 2017 |  BC Week In Review  |  Financial News

CIRM awards $44M in grants

The California Institute for Regenerative Medicine awarded more than $44 million over four grants to develop stem cell therapies to treat stroke, a fetal blood disorder and acute myelogenous leukemia (AML). CIRM awarded $20 million...
22:22 , Jun 30, 2017 |  BC Extra  |  Financial News

CIRM awards $44M in grants

The California Institute for Regenerative Medicine awarded more than $44 million over four grants to develop stem cell therapies to treat stroke, a fetal blood disorder and acute myelogenous leukemia (AML). CIRM awarded $20 million...
19:41 , Jun 2, 2017 |  BioCentury  |  Product Development

Ears wide open

Based on unmet need alone, hearing loss should have been every bit as attractive to investors and drug developers as ophthalmic diseases, which entered a renaissance in the mid-2000s resulting in a multibillion-dollar market for...
16:58 , May 31, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Colorectal cancer Cell culture and mouse studies identified a JAG2 -targeting MT-TL1 fragment that could help treat colorectal cancer. The fragment consisted of a dicer 1 ribonuclease type III (DICER1)-cleaved form of MT-TL1 and...
22:06 , May 11, 2017 |  BC Innovations  |  Tools & Techniques

Stemming the tide

OncoMed’s bad April has all the hallmarks of a death knell for the once-promising technology of cancer stem cells, adding to the pile of preclinical breakthroughs that didn’t translate to the clinic. But many insiders...
20:33 , Apr 21, 2017 |  BC Week In Review  |  Clinical News

Brontictuzumab: Ph Ib discontinued

OncoMed said it will discontinue an open-label, dose-escalation, U.S. Phase Ib trial in mCRC patients after data showed that third-line treatment with IV brontictuzumab plus Lonsurf trifluridine/tipiracil was not well tolerated and led to grade...